Fluvoxamine
mRNA synthesis
In vitro transcription of capped mRNA with modified nucleotides and Poly(A) tail
Tyramide Signal Amplification (TSA)
TSA (Tyramide Signal Amplification), used for signal amplification of ISH, IHC and IC etc.
Phos Binding Reagent Acrylamide
Separation of phosphorylated and non-phosphorylated proteins without phospho-specific antibody
Cell Counting Kit-8 (CCK-8)
A convenient and sensitive way for cell proliferation assay and cytotoxicity assay
SYBR Safe DNA Gel Stain
Safe and sensitive stain for visualization of DNA or RNA in agarose or acrylamide gels.
Inhibitor Cocktails
Protect the integrity of proteins from multiple proteases and phosphatases for different applications.
Fluvoxamine是一种抗抑郁药,其在药理学上选择性抑制5-羟色胺的再摄取。Serotonin也称为5-HT,是一种单胺神经递质,具有多种生理学作用如心情、食欲和睡眠 [1]。
体外实验:Fluvoxamine有效抑制血小板和脑突触体的5-HT摄取[1]。Fluvoxamine(10 mg/kg)增加了所有脑区的[5-HT]ex水平,并且还增加了纹状体中的[DA]ex水平。与基线相比,Fluvoxamine(10 mg/kg)与quetiapine(10 mg/kg)的组合增加了所有脑区中[DA]ex和[5-HT]ex水平。药物组合使用显著增加前额叶皮层和丘脑中[DA]ex水平,而单一疗法中的fluvoxamine和quetiapine均不影响[DA]ex水平[2]。Fluvoxamine通过作用于下行5-HT纤维和脊髓5-HT2A或5-HT2C受体对神经性疼痛产生抗异常性疼痛作用,通过作用于5-HT3受体对急性机械性疼痛产生抗伤害作用[3]。
在体实验:腹腔单次注射fluvoxamine 10和30 mg/kg以剂量依赖性方式增强海马mPFC通路中的突触功效[4]。腹腔注射fluvoxamine 10和30 mg/kg抑制了麻醉大鼠的海马CA1区的长时程增强(LTP)。腹腔注射0.5 mg/kg 5-HT(1A)受体拮抗剂NAN-190完全逆转了fluvoxamine(30 mg/kg,i.p.)对LTP的抑制 [5]
参考文献:
[1]. Claassen V, Davies JE, Hertting G, Placheta P. Fluvoxamine, a specific 5-hydroxytryptamine uptake inhibitor. Br J Pharmacol.1977 Aug;60(4):505-16.
[2]. Denys D1, Klompmakers AA,Westenberg HG. Synergistic dopamine increase in the rat prefrontal cortex with the combination of quetiapine and fluvoxamine. Psychopharmacology (Berl). 2004 Nov;176(2):195-203. Epub 2004 May 11.
[3]. Honda M1, Uchida K, Tanabe M, Ono H. Fluvoxamine, a selective serotonin reuptake inhibitor, exerts its antiallodynic effects on neuropathic pain in mice via 5-HT2A/2C receptors. Neuropharmacology. 2006 Sep;51(4):866-72. Epub 2006 Jul 17.
[4]. Ohashi S1, Matsumoto M, Otani H, Mori K, Togashi H, Ueno K, Kaku A, Yoshioka M. Changes in synaptic plasticity in the rat hippocampo-medial prefrontal cortex pathway induced by repeated treatments with fluvoxamine. Brain Res.2002 Sep 13;949(1-2):131-8.
[5]. Kojima T1, Matsumoto M, Togashi H, Tachibana K,Kemmotsu O, Yoshioka M. Fluvoxamine suppresses the long-term potentiation in the hippocampal CA1 field of anesthetized rats: an effect mediated via 5-HT1A receptors. Brain Res. 2003 Jan 3;959(1):165-8.
Physical Appearance | A yellow liquid |
Storage | Store at -20°C |
M.Wt | 318.33 |
Cas No. | 54739-18-3 |
Formula | C15H21F3N2O2 |
Solubility | insoluble in H2O; ≥15.92 mg/mL in DMSO; ≥76.3 mg/mL in EtOH |
Chemical Name | 2-[(E)-[5-methoxy-1-[4-(trifluoromethyl)phenyl]pentylidene]amino]oxyethanamine |
SDF | Download SDF |
Canonical SMILES | COCCCCC(=NOCCN)C1=CC=C(C=C1)C(F)(F)F |
运输条件 | 蓝冰运输或根据您的需求运输。 |
一般建议 | 不同厂家不同批次产品溶解度各有差异,仅做参考。若实验所需浓度过大至产品溶解极限,请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存,请尽快用完。 |
动物实验[1]: | |
动物模型 |
5-羟色胺缺乏小鼠 |
剂量 |
30 mg/kg,腹腔注射 |
应用 |
Fluvoxamine通过减少5-HT纤维和脊髓5-HT2A或5-HT2C受体,发挥抗神经性疼痛的作用,通过对5-HT 3受体的作用发挥抗急性机械性疼痛的作用。在5-羟色胺缺乏的小鼠中,fluvoxamine引起的止痛作用被明显减弱。 |
注意事项 |
请测试所有化合物在室内的溶解度,实际溶解度和理论值可能略有不同。这是由实验系统的误差引起的,属于正常现象。 |
References: [1] Honda M1, Uchida K, Tanabe M, Ono H. Fluvoxamine, a selective serotonin reuptake inhibitor, exerts its antiallodynic effects on neuropathic pain in mice via 5-HT2A/2C receptors. Neuropharmacology. 2006 Sep;51(4):866-72. Epub 2006 Jul 17. |
质量控制和MSDS
- 批次: